A real-world study investigating the actual effects of combined chemotherapy and PD-1/PD-L1 inhibitors in the treatment of advanced NSCLC revealed that patients with negative PD-L1 expression experienced poorer prognoses following combined treatment (8). This evidence concerns the gene CD274 and non-small cell lung carcinoma.